Kenai Therapeutics
Company developing allogeneic neuron replacement cell therapies for neurological disorders
Kenai Therapeutics is a biotechnology company pioneering next generation approaches to cure neurological disorders. The Company utilizes allogeneic induced pluripotent stem cell (iPSC) technology, a Nobel Prize-winning breakthrough that enables scientists to manufacture many human cell types, in order to advance Kenai’s off-the-shelf neuron replacement therapeutics. By focusing on an iPSC technology platform, and forging partnerships with global leaders in surgical delivery and clinical development, Kenai is dedicated to advancing a best-in-class pipeline targeting neurological diseases.
Visit website: https://www.kenaitx.com/
Details last updated 03-Mar-2024
Kenai Therapeutics News
Kenai secures $82m to advance cell therapy for Parkinson's disease
Longevity Technology - 01-Mar-2024
iPSC-based therapy set for phase 1 trials to replace lost neurons and modify disease course
Read more...